Dermatitis News and Research

Latest Dermatitis News and Research

Provectus presents additional data on PV-10 at two separate melanoma conferences

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at two separate conferences.

30 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Anacor Pharmaceuticals announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis.

28 Jun 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.

16 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

Invida announces launch of novel atopic dermatitis symptomatic treatment

Invida Group Private Limited reaffirmed its commitment to patients in Asia Pacific by announcing the launch of a novel atopic dermatitis symptomatic treatment, Atopiclair, which will be available to patients across Asia in second half of 2011.

26 May 2011

Gerber Products receives first qualified health claim from FDA for infant formulas

Today, Gerber Products Company, a part of the Nestlé family, announced that Gerber Good Start milk-based formulas are the first and only infant formulas that meet the criteria for a qualified health claim.

26 May 2011

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

24 May 2011

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

A protein isolated from beneficial bacteria found in yogurt and dairy products could offer a new, oral therapeutic option for inflammatory bowel disorders, suggests a study led by Vanderbilt University Medical Center researcher Fang Yan, M.D., Ph.D.

24 May 2011

New analytical method can improve detection of dimethyl fumarate in leather and footwear

Researchers at Igualada School of Engineering, a school associated with the Universitat Politècnica de Catalunya, have developed a new analytical method that improves detection of dimethyl fumarate in leather and footwear.

24 May 2011

USPTO grants four key patents for Alvine's proteases to detect celiac disease

Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, today announced that the United States Patent and Trademark Office has issued four key patents: 7,943,312; 7,928,056; 7,923,532; and 7,910,541, protecting various aspects of Alvine's core technology.

19 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.

18 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

Imaginary bugs flummox dermatologists

It is known that some people have the “delusional bug syndrome” and are convinced that bugs, worms, germs, or other creepy crawlers are infesting their skin and often see skin doctor after skin doctor to find out what is causing the infestation. Often, patients bring in samples of the insect and request a skin biopsy.

17 May 2011

Anacor first quarter revenues increase to $2.2 million

Anacor Pharmaceuticals reviewed today its first quarter accomplishments and reported financial results for the quarter ended March 31, 2011.

5 May 2011

Dermatitis News and Research

Latest Dermatitis News and Research

Provectus presents additional data on PV-10 at two separate melanoma conferences

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Invida announces launch of novel atopic dermatitis symptomatic treatment

Gerber Products receives first qualified health claim from FDA for infant formulas

Lx Therapies, BioCis partner to form Laurantis Pharma

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

New analytical method can improve detection of dimethyl fumarate in leather and footwear

USPTO grants four key patents for Alvine's proteases to detect celiac disease

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Imaginary bugs flummox dermatologists

Anacor first quarter revenues increase to $2.2 million

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Dermatitis News and Research

Latest Dermatitis News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in